MHRA issues UK marketing approval for Biocon Biologics biosimilar aflibercept (YESAFILI®)

News
Article

The company received marketing authorisation approval in the EU earlier this year

A photo of downtown London. Image credit: ©zgphotography – stock.adobe.com

YESAFILI® received a marketing authorisation from the European Commission in September. Image credit: ©zgphotography – stock.adobe.com

On Monday, Biocon Ltd. announced its subsidiary Biocon Biologics Limited received marketing authorisation approval from the United Kingdom’s Medicines and Healthcare products Regulatory Agency for its product YESAFILI®. According to a press release from Biocon, YESAFILI is a biosimilar with comparable efficacy, safety and quality to the reference product Eylea® (aflibercept).1

Earlier this year, YESAFILI underwent the approval process in the European Union. The biosimilar received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use in July and received a marketing authorisation from the European Commission in September.

Biocon’s YESAFILI is intended for treatment of a number of ocular conditions, including neovascular age-related macular degeneration, visual impairment due to myopic choroidal neovascularisation, visual impairment due to diabetic macular oedema and visual impairment due to macular oedema secondary to retinal vein occlusion. In the news release, Biocon expressed that the biosimilar approval will help the company expand its product portfolios in ophthalmology, diabetes care and oncology.

In July, Shreehas Tambe, CEO and managing director of Biocon Biologics, commented on the positive CHMP opinion for YESAFILI.2 "This is further confirmation of our strong commitment to providing high-quality and affordable medicines and represents another significant milestone as we continue to expand our biosimilar offerings across the globe,” Tambe said.


References

  1. Biocon Biologics Receives MHRA, UK Approval for YESAFILI®, Biosimilar Aflibercept. News release. Biocon Ltd. 13 November, 2023. https://www.biocon.com/biocon-biologics-receives-mhra-uk-approval-for-yesafili-biosimilar-aflibercept/
  2. Hayes, H. European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issues positive opinion for aflibercept biosimilar YESAFILI®. Ophthalmology Times Europe. 25 July, 2023. Accessed 13 November, 2023. https://europe.ophthalmologytimes.com/view/chmp-european-positive-opinion-aflibercept-biosimilar-yesafili

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
Related Content
© 2025 MJH Life Sciences

All rights reserved.